Peripheral arterial disease (PAD) is caused by atherosclerosis that results in obstructions in the arteries to the lower extremities. The prevalence of PAD is nearly equal to that of ischemic heart disease. In a sizeable fraction of patients with severe forms of PAD, there is a complete occlusion in one or more major arteries, and thus blood flow to the distal lower limb becomes dependent on the extent, number and function of collateral blood vessels. There are no medical therapies available for patients with PAD that favorably modulate collateral number or function and perfusion to the lower extremity. The concept of stimulating new blood vessel growth ('therapeutic angiogenesis') to improve limb perfusion in patients with PAD is now a 20 year old investigational strategy. The vast majority of human trials use gene transfer by intra-muscular (IM) delivery with plasmid or adenoviral vectors. After dozens of trials and thousands of subjects, success in this field has been meager. Human studies have failed to convincingly show therapeutic gene expression following IM injection, and this may well account for the failure of clinical trials in therapeutic angiogenesis conducted to date. Adeno-associated virus can be transformational in providing the link from mouse to man for therapeutic angiogenesis in PAD. Following systemic (intravenous) delivery, several AAV serotypes efficiently transduce skeletal muscle. While PAD could potentially limit the access of AAV9 to ischemic muscle, we found enhanced gene expression in ischemic compared to non-ischemic muscle following systemic delivery and we have examined potential mechanisms. Building on this foundation, the central hypothesis of this revised proposal is that bioengineered AAV9 vectors are uniquely suited to accomplish therapeutic angiogenesis in PAD via local delivery using isolated limb perfusion. The three complementary but independent Aims are to:
Specific Aim 1 : Optimize AAV9-mediated gene delivery to ischemic muscle using systemic vs. isolated limb perfusion in small and large animal models of PAD as a link to clinical application. We will use reporter genes and quantitative biodistribution studies of gene expression to compare systemic versus local delivery in ischemic muscle relative to off-target tissues in mice and pigs. Further, we will incorporate hypoxia-response elements and examine immune responses in both murine and porcine hind-limb ischemia models of PAD.
Specific Aim 2 : Establish that ischemia-induced desialylation, which results in a difference in the ratio of sialylated to desialylated glycoproteins, is a mechanism for enhanced gene expression in ischemic muscle in pre-clinical and clinical PAD subjects vs. non-PAD controls.
Specific Aim 3 : Determine the efficacy of AAV-mediated gene therapy delivered via isolated limb perfusion in both mouse and porcine hind-limb ischemia models of PAD. In this aim, we will compare ADAM12 vs. EcSOD gene therapy in the mouse hind-limb ischemia model of PAD, then confirm the efficacy of the most effective gene therapy in the porcine hind-limb model of PAD in collaboration with Dr. Albert Sinusas (Yale).
Peripheral arterial disease (PAD) is a major health problem caused by atherosclerosis that impairs blood flow to the legs. Currently, there are no medical therapies that have the ability to improve blood flow to the legs of patients suffering from the devastating symptoms of PAD. This project will combine the expertise of two teams of established clinical investigators and scientists at the University of Virginia and Yale University to optimize a promising new gene delivery system that has the potential to overcome the limitations inherent in all previous attempts to translate gene therapy for PAD into clinical practice. The animal experiments conducted in mice at UVA will systematically be validated at Yale in a large animal model with more clinical relevance.
|Leslie, Jhansi L; Annex, Brian H (2018) The Microbiome and Endothelial Function. Circ Res 123:1015-1016|
|Heuslein, Joshua L; McDonnell, Stephanie P; Song, Ji et al. (2018) MicroRNA-146a Regulates Perfusion Recovery in Response to Arterial Occlusion via Arteriogenesis. Front Bioeng Biotechnol 6:1|
|Zhu, Hongling; Wang, Tao; John Lye, Robert et al. (2018) Neuraminidase-mediated desialylation augments AAV9-mediated gene expression in skeletal muscle. J Gene Med 20:e3049|
|Ryan, Terence E; Yamaguchi, Dean J; Schmidt, Cameron A et al. (2018) Extensive skeletal muscle cell mitochondriopathy distinguishes critical limb ischemia patients from claudicants. JCI Insight 3:|
|Heuslein, Joshua L; Gorick, Catherine M; McDonnell, Stephanie P et al. (2018) Exposure of Endothelium to Biomimetic Flow Waveforms Yields Identification of miR-199a-5p as a Potent Regulator of Arteriogenesis. Mol Ther Nucleic Acids 12:829-844|
|Ganta, Vijay Chaitanya; Annex, Brian H (2017) LMO2 (LIM Domain Only 2) and Endothelial Cell Migration in Developmental and Postnatal Angiogenesis. Arterioscler Thromb Vasc Biol 37:1806-1808|
|McClung, Joseph M; McCord, Timothy J; Ryan, Terence E et al. (2017) BAG3 (Bcl-2-Associated Athanogene-3) Coding Variant in Mice Determines Susceptibility to Ischemic Limb Muscle Myopathy by Directing Autophagy. Circulation 136:281-296|
|Ganta, Vijay Chaitanya; Choi, Min; Kutateladze, Anna et al. (2017) VEGF165b Modulates Endothelial VEGFR1-STAT3 Signaling Pathway and Angiogenesis in Human and Experimental Peripheral Arterial Disease. Circ Res 120:282-295|
|Clegg, Lindsay E; Ganta, Vijay C; Annex, Brian H et al. (2017) Systems Pharmacology of VEGF165b in Peripheral Artery Disease. CPT Pharmacometrics Syst Pharmacol 6:833-844|
|Iyer, Sunil R; Annex, Brian H (2017) Therapeutic Angiogenesis for Peripheral Artery Disease: Lessons Learned in Translational Science. JACC Basic Transl Sci 2:503-512|
Showing the most recent 10 out of 16 publications